Standard genetic approaches allow the production of protein composites by fusion of polypeptides in head-to-tail fashion. Some applications would benefit from constructions that are genetically impossible, such as the site-specific linkage of proteins via their N or C termini, when a remaining free terminus is required for biological activity. We developed a method for the production of N-to-N and C-to-C dimers, with full retention of the biological activity of both fusion partners and without inflicting chemical damage on the proteins to be joined. We use sortase A to install on the N or C terminus of proteins of interest the requisite modifications to execute a strain-promoted copper-free cycloaddition and show that the ensuing ligation proceeds efficiently. Applied here to protein-protein fusions, the method reported can be extended to connecting proteins with any entity of interest.antibodies | bioorthogonal | engineering | transacylation T he creation of protein-protein fusions, by genetic means, chemically, or enzymatically, has become an important tool to study cell biological and biochemical problems. Genetic fusions with fluorescent proteins are widely used to visualize their (sub)cellular localization in situ and in vivo (1). Coexpression of two orthogonally labeled chimeras allows the study of protein colocalization and dynamics of receptor dimerization. Moreover, protein fusions have been used to evaluate the biological relevance of otherwise transient protein complexes. Fusion or cross-linking of two or more of the interacting proteins can stabilize protein complexes and has been used to explore signaling and (hetero)dimerization of G-protein-coupled receptors (2, 3), chemokines, and cytokines (4-6).Besides being useful biochemical tools, chimeric proteins are also promising as treatment options for cancer, autoimmune diseases, lysosomal storage diseases, and brain disorders (7-10). Toxins have been conjugated to antibodies, growth factors, and cytokines as a means of delivering these payloads to malignant cells that express the counterstructures recognized by such fusion proteins, to kill tumor cells while minimizing collateral damage (10-12). Bispecific antibodies, prepared by fusing two singlechain variable fragments (scFV) of immunoglobulins, may combine an antigen-binding domain specific for a tumor cell with a CD3 receptor-binding domain specific for T cells (13). These compounds then allow the T cells to exert cytotoxic activity or cytokine release locally and so elicit the desired antitumor response. Finally, protein fusion strategies have been used to prepare structurally defined biomaterials (14).The production and purification of fusion proteins remains a biotechnological challenge. To obtain an active product, both domains of the chimera must adopt the native fold, without modification of residues and regions that are required for activity. The standard method to produce such proteins is by genetic fusion of the ORFs of the two proteins or protein fragments. Although recombinant expressi...